September 13th 2025
Researchers will investigate a gene in the eye that is crucial for normal vision, but can cause retinal diseases when mutated that often lead to blindness.
Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases
December 19th 2024Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges persist, including treatment burden, adherence, and identifying optimal dosing regimens for individual patients.
Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101
December 6th 2024The company begins Phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ophthalmic models suggest potential for treating dry AMD, glaucoma, and neurodegenerative eye diseases.
USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy
November 25th 2024The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing a therapy for dry age-related macular degeneration, one of the leading causes of blindness in older adults.
FDA authorizes marketing of Valeda Light Delivery System for treatment of patients with dry AMD
November 12th 2024"The De Novo authorization established Valeda as the first device for treatment of dry AMD patients with vision loss and creates a threshold for this novel class of photobiomodulation (PBM) devices..."
Noninvasive choroidal vessel analysis using deep learning: A novel approach to OCT angiography
November 11th 2024Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables detailed 3D visualization of choroidal vessels from OCT scans. This technique could improve diagnostics for retinal diseases like macular degeneration, offering a safer alternative to traditional methods.
Rensselaer Polytechnic Institute researchers receive grant to study potential dry AMD treatment
November 8th 2024A $6.4 million grant over 5 years from the National Institutes of Health’s National Eye Institute was awarded conduct drug development work and investigational new drug (IND)-enabling toxicology studies.